ReviewFrontiers in immunology2026
Phosphoregulation of interleukin-1 receptor-associated kinase 1 in inflammatory signaling.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-1 receptor-associated kinase 1 (IRAK1) is a serine/threonine kinase that functions as a central transducer of Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling, linking pathogen recognition to the activation of nuclear factor kappa B (NF-κB), mitogen-activated protein kinases (MAPK), and interferon regulatory factors (IRFs). Although the role of IRAK1 in innate immune signaling is well established, its regulatory complexity remains incompletely characterized, particularly regarding the dynamic phosphorylation landscape that governs activation, substrate specificity, and signal termination. This review presents a systematic phosphoproteomics map of IRAK1 phosphorylation, integrating 213 profiling and 33 differential mass spectrometry-based phosphoproteomic datasets from 56 studies. Eighteen phosphosites were identified in the profiling datasets and 16 in the differential datasets across independent expression and acquisition conditions. Among these, Ser131 (detected in 128 profiling and 26 differential datasets) and Ser110 (detected in 26 profiling and nine differential datasets) were the most frequently observed sites. Most high-frequency phosphosites are located within the serine/threonine kinase domain and the C-terminal proline/serine/threonine-rich (ProST) regulatory region of the protein. However, frequent detection does not necessarily indicate functional significance, and these sites are potential candidates for targeted validation. In addition to canonical phosphorylation, this review evaluates the coordinated interplay among phosphorylation, K63/K48-linked ubiquitination, and SUMOylation, which together determine whether signaling is propagated or terminated. We also discuss the non-canonical functions of IRAK1 in transcriptional regulation, antiviral defense, cytoskeletal organization, and oncogenic signaling, and evaluate current pharmacological inhibitors of IRAK1, including Pacritinib, JH-X-119-01, 1, 4-naphthoquinone, and rosoxacin. Overall, this review provides a systematic, data-informed framework for prioritizing phosphosite-specific functional studies to identify phospho-dependent interaction interfaces as potential targets for precision clinical interventions and biomarker development in inflammatory diseases and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.